Articles about Biotechnology, Pharmaceutical and Healthcare

11:35 EDT 25th October 2016 | BioPortfolio

Latest Articles on life science, biotechnology, pharmaceutical and healthcare topics and current issues.

Showing News Articles 1–25 of 82,000+

Tuesday 25th October 2016

Moss-based manufacturing technology enhances pharmaceutical protein yield

Developer of next-gen therapeutics, Greenovation, has increased the yields of pharmaceutical proteins produced using Its moss-based ByroTechnology.

Mosca GmbH: Biobasierte Umreifungsbänder

Die Mosca GmbH, ein familiengeführtes Unternehmen, stellt Umreifungsmaschinen und Umreifungsbänder für den Transport zahlreicher Güter her. Nachhaltigkeit ist eines der zentralen Anliegen des Unternehmens und wird bereits seit Jahren erfolgreich umgesetzt. Ein weiterer Schritt in Sachen Nachhaltigkeit ist ein biobasiertes Umreifungsband aus Polymilchsäure (PLA), einem nachwachsenden Rohstoff,...

Indonesian doctors risk losing licence if they castrate paedophiles

Doctors in Indonesia who perform chemical castration on convicted paedophiles risk censure by their professional body, the Indonesian Medical Association, and put their licence to practise in...

Pluristem raises $30m from Chinese investors

Innovative Medical Management Co. Ltd. is investing in the Israeli placenta-based cell therapy products developer.

HedgePath Pharmaceuticals Touts Positive Interim Data in Phase 2b Cancer Trial

NewsBCCNS patients have a rare genetic mutation which can lead to the growth of as many as hundreds of primary basal cell carcinomas on the skin, even in non-sun exposed areas.

Study Reveals Mouse Decision-making More Complex Than Once Thought

NewsWorking with dot-counting mice running through a virtual-reality maze, scientists have found that in order to navigate space rodent brains rely on a cascade of neural signals that culminate in a single decision that prompts the animal to choose one direction over another.

Increasing Muscle Strength Can Improve Brain Function

NewsIncreased muscle strength leads to improved brain function in adults with Mild Cognitive Impairment (MCI), new results from a recent trial has revealed.

NHS must find ways to speed access to new drugs and technologies

New drugs, diagnostic tools, and healthcare technologies could be adopted more quickly if the NHS took a fresh approach, according to the final report of the Accelerated Access Review.1Streamlining...

ANA 2016: Risk Factors with Neurological Disorders

Award-winning posters presented during the American Neurological Association Annual Meeting discussed risks in stroke, MS, and migraine.

FDA Approves Merck's Keytruda in Metastatic NSCLC as First-Line Treatment

NewsKEYTRUDA (pembrolizumab) should be withheld or discontinued and corticosteroids administered when appropriate.Topics: 

Organoid Culture Handbook

Product AnnouncementAMSBIO announces an extended and updated edition of its popular Organoid Culture Handbook. Launched at the EMBO Symposium on Organoids: Modelling Organ Development and Disease in 3D Culture, the new 24-page handbook includes valuable information about the latest available products, protocols, example results and research paper citations.

PharmaMar (PHM) - Myeloma filed, breast results by year end

Edison Investment Research - Pharmaceutical & healthcare - PharmaMar: PharmaMar has delivered impressive progress in 2016, including filing for Aplidin approval for myeloma in Europe, and the launch of small cell lung cancer (PM1183) and lymphoma (Aplidin) pivotal trials. News likely before year-end includes breast cancer Phase II results and full recruitment in the PM1183 ovarian Phase III. H116 ...

Achillion Pharmaceuticals (ACHN) - Triple regimen is a potential six-week treatment

Edison Investment Research - Pharmaceutical & healthcare - Achillion Pharmaceuticals: Updated interim results from the Phase IIa dose ranging study ALS-022335, simeprevir and odalasvir for the treatment of genotype 1 hepatitis C virus (HCV), were announced at the European Association for the Study of the Liver conference in September 2016. The study showed a sustained virologic response at 12 week...

Intec Pharma (NTEC) - A new pill delivering best-in-class results

Edison Investment Research - Pharmaceutical & healthcare - Intec Pharma: We are initiating our coverage of Intec Pharma, a drug delivery company that has developed a novel drug delivery device termed the accordion pill (AP), with advantages for drugs with poor solubility or absorption. The company currently has two disclosed development programmes: AP-CDLD, a controlled release formulation of carb...

Nexstim (NXTMH) - More data please

Edison Investment Research - Pharmaceutical & healthcare - Nexstim: The FDA has told Nexstim it may accept a “limited-sized” further trial plus additional analysis of the Phase III (NICHE) study. While this is positive for Nexstim – the FDA did not reject the application – it delays any approval to at least 2019. The new design is unlikely to be confirmed before H117. In ou...

C4X Discovery (C4XD) - Strategic collaboration with Evotec

Edison Investment Research - Pharmaceutical & healthcare - C4X Discovery Holdings: C4X Discovery has announced a new strategic collaboration with Evotec, which builds on a previous agreement (January 2015) to develop new small molecule drugs across a range of targets, therapeutic areas and stages of development. The agreement is a risk-shared multi-target programme. This is a positive development ...

Tonix Pharmaceuticals (TNXP) - Fibromyalgia setback, focus on PTSD

Edison Investment Research - Pharmaceutical & healthcare - Tonix Pharmaceuticals: Tonix reported that the Phase III trial of TNX-102 SL for the treatment of fibromyalgia did not reach its primary endpoint of the proportion of 30% responders compared to placebo (p=0.095). The company also announced that it will discontinue the fibromyalgia program and focus its resources on advancing TNX-102 SL for...

Medigene (MDG1) - Strategic alliance validates TCR technology

Edison Investment Research - Pharmaceutical & healthcare - Medigene: Medigene has announced an alliance with bluebird bio, a prominent T-cell immunology company. It is Medigene’s first commercial partnering agreement based on its proprietary T-cell receptor (TCR) technology platform. The collaboration will seek to identify four TCR therapeutic candidates against four targets. This is a posit...

SkyePharma (SKP) - Termination of coverage

Edison Investment Research - Pharmaceutical & healthcare - Skyepharma: Edison Investment Research is terminating coverage on SkyePharma (SKP). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. ISIN: GB00B3BFNB64

4SC (VSC) - Positive detailed analysis of Phase II trial data

Edison Investment Research - Pharmaceutical & healthcare - 4SC: 4SC has announced positive Phase II results from a more detailed analysis of the HCC Yakult Phase II trial data, which we believe could lead to further clinical development. It has also recently announced the sale of its immunology portfolio (Vidofludimus and a cytokine inhibitor), which further streamlines the company’s focus f...

Adherium (ADR) - Commercial roll-out still at pilot stage

Edison Investment Research - Pharmaceutical & healthcare - Adherium: Adherium’s FY16 sales of A$2.6m were 7% below expectations, likely due to a pause in commercial supply to AstraZeneca (AZN) in H216 as the pharma used inventory purchased in CY15 for initial market testing. The net loss of A$7.9m included A$1.4m of one-off costs. We have amended near-term forecasts to allow for a slower ini...

Orexo (ORX) - Good things come in threes

Edison Investment Research - Pharmaceutical & healthcare - Orexo: Orexo has delivered on three key newsflow items, which should contribute to driving increased Zubsolv use in the treatment of opioid addiction. Submission of Zubsolv’s MAA with the EMA means that first launch ex-US could come from 2018 onwards. FDA approval of a new low dose provides greater dosing flexibility. Positive data f...

UDG Healthcare (UDG) - Investor day feedback: Markets, Margins, M&A

Edison Investment Research - Pharmaceutical & healthcare - UDG Healthcare: UDG held a capital markets day on 27 September hosted by senior management across all divisions and regions. Below we discuss our key takeaways from this meeting. ISIN: IE0033024807

Selvita (SLV) - Continuous growth fuels capacity expansion

Edison Investment Research - Pharmaceutical & healthcare - Selvita: Selvita delivered strong overall organic growth in Q216, while the mid-year backlog supports our estimated double-digit sales growth in 2016. The company is accelerating its capacity expansion with a new long-term research facility development project. If this goes according to plan, the total number of employees could be boosted ...

Consort Medical (CSRT) - New impetus for injectables franchise

Edison Investment Research - Pharmaceutical & healthcare - Consort Medical: Bespak’s first deal for its proprietary Syrina autoinjector platform is with an undisclosed major global biopharma. Syrina is based on proprietary VapourSoft technology that uses a liquid gas propellant (rather than a conventional spring) to provide the force for drug delivery. Bespak’s ability to customise its...

Quick Search